Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3096)
All Articles published online
|
Apr 7, 2005 (publication date) through Apr 20, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bondanelli M, Ambrosio MR, Zatelli MC, Cavazzini L, Al Jandali Rifa’y L, degli Uberti EC. Regression of liver metastases of occult carcinoid tumor with slow release Lanreotide therapy. World J Gastroenterol 2005; 11(13): 2041-2044 [PMID: 15801004 DOI: 10.3748/wjg.v11.i13.2041] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i13/2041.htm |
| Number | Citing Articles |
| 1 |
Larry K. Kvols, Eugene A. Woltering. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anti-Cancer Drugs 2006; 17(6): 601 doi: 10.1097/01.cad.0000210335.95828.ed
|
| 2 |
J. Bendelow, E. Apps, L.E. Jones, G.J. Poston. Carcinoid syndrome. European Journal of Surgical Oncology (EJSO) 2008; 34(3): 289 doi: 10.1016/j.ejso.2007.07.202
|
| 3 |
Joel E. Rosenberg, Jacob A. Albersheim, Niranjan J. Sathianathen, Paari Murugan, Christopher J. Weight. Five New Cases of Primary Renal Carcinoid Tumor: Case Reports and Literature Review. Pathology & Oncology Research 2020; 26(1): 341 doi: 10.1007/s12253-018-0481-x
|
| 4 |
Alysandra Lal, Herbert Chen. Treatment of advanced carcinoid tumors. Current Opinion in Oncology 2006; 18(1): 9 doi: 10.1097/01.cco.0000198018.53606.62
|
| 5 |
FIONA GRAEME-COOK. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. 2009; : 653 doi: 10.1016/B978-141604059-0.50028-X
|
| 6 |
Kjell E Öberg. Management of neuroendocrine tumors: current and future therapies. Expert Review of Endocrinology & Metabolism 2011; 6(1): 49 doi: 10.1586/eem.10.81
|
| 7 |
Esther Una Cidon. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World Journal of Gastrointestinal Oncology 2017; 9(1): 4-20 doi: 10.4251/wjgo.v9.i1.4
|
| 8 |
Marialuisa Appetecchia, Roberto Baldelli. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. Journal of Experimental & Clinical Cancer Research 2010; 29(1) doi: 10.1186/1756-9966-29-19
|
| 9 |
Pier Luigi Filosso, Alberto Oliaro, Enrico Ruffini, Giulia Bora, Paraskevas Lyberis, Sofia Asioli, Luisa Delsedime, Alberto Sandri, Francesco Guerrera. Outcome and Prognostic Factors in Bronchial Carcinoids: A Single-Center Experience. Journal of Thoracic Oncology 2013; 8(10): 1282 doi: 10.1097/JTO.0b013e31829f097a
|
| 10 |
Shizhang Song, Xin Liang, Bo Jiang, Sichuan Hou. Primary renal large cell neuroendocrine carcinoma with horseshoe kidney: A case report. Asian Journal of Surgery 2021; 44(4): 702 doi: 10.1016/j.asjsur.2021.01.008
|
| 11 |
Michael Michael, Rocio Garcia-Carbonero, Matthias M. Weber, Catherine Lombard-Bohas, Christos Toumpanakis, Rodney J. Hicks. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. The Oncologist 2017; 22(3): 272 doi: 10.1634/theoncologist.2016-0305
|
| 12 |
Péter Igaz, Károly Rácz, Zsolt Tulassay. Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin A for clinical follow-up. Orvosi Hetilap 2007; 148(49): 2343 doi: 10.1556/oh.2007.28231
|
| 13 |
Peter Igaz, Károly Rácz, Zsolt Tulassay. Effective Treatment of a Hormonally Inactive Carcinoid Tumour with Somatostatin Analogues: Application of Serum Chromogranin A for Clinical Follow-Up. Hungarian Medical Journal 2007; 1(4): 463 doi: 10.1556/HMJ.1.2007.28231
|